Compare ASTRAZENECA PHARMA with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs J.B.CHEMICALS - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA J.B.CHEMICALS ASTRAZENECA PHARMA/
J.B.CHEMICALS
 
P/E (TTM) x 129.7 33.1 391.8% View Chart
P/BV x 36.4 6.2 591.3% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ASTRAZENECA PHARMA   J.B.CHEMICALS
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
J.B.CHEMICALS
Mar-18
ASTRAZENECA PHARMA/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1,278363 352.0%   
Low Rs883255 346.1%   
Sales per share (Unadj.) Rs228.4169.1 135.0%  
Earnings per share (Unadj.) Rs10.416.6 62.4%  
Cash flow per share (Unadj.) Rs16.323.4 69.4%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.6 0.0%  
Book value per share (Unadj.) Rs98.8172.5 57.3%  
Shares outstanding (eoy) m25.0083.57 29.9%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x4.71.8 258.9%   
Avg P/E ratio x104.218.6 559.9%  
P/CF ratio (eoy) x66.413.2 503.4%  
Price / Book Value ratio x10.91.8 610.5%  
Dividend payout %012.0 0.0%   
Avg Mkt Cap Rs m27,00825,827 104.6%   
No. of employees `0001.43.8 35.9%   
Total wages/salary Rs m1,5352,511 61.1%   
Avg. sales/employee Rs Th4,210.93,747.4 112.4%   
Avg. wages/employee Rs Th1,132.2665.7 170.1%   
Avg. net profit/employee Rs Th191.1367.8 52.0%   
INCOME DATA
Net Sales Rs m5,71014,135 40.4%  
Other income Rs m123366 33.5%   
Total revenues Rs m5,83314,501 40.2%   
Gross profit Rs m4632,178 21.3%  
Depreciation Rs m147570 25.9%   
Interest Rs m035 0.0%   
Profit before tax Rs m4381,940 22.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m179552 32.4%   
Profit after tax Rs m2591,387 18.7%  
Gross profit margin %8.115.4 52.6%  
Effective tax rate %40.828.5 143.4%   
Net profit margin %4.59.8 46.2%  
BALANCE SHEET DATA
Current assets Rs m3,20910,470 30.7%   
Current liabilities Rs m2,0702,749 75.3%   
Net working cap to sales %20.054.6 36.5%  
Current ratio x1.63.8 40.7%  
Inventory Days Days7255 131.1%  
Debtors Days Days3578 45.0%  
Net fixed assets Rs m7905,811 13.6%   
Share capital Rs m50167 29.9%   
"Free" reserves Rs m2,41914,248 17.0%   
Net worth Rs m2,46914,416 17.1%   
Long term debt Rs m00-   
Total assets Rs m4,60517,649 26.1%  
Interest coverage xNM56.6-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.8 154.8%   
Return on assets %5.68.1 69.8%  
Return on equity %10.59.6 109.0%  
Return on capital %17.713.7 129.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3006,164 4.9%   
Fx outflow Rs m2,0151,334 151.0%   
Net fx Rs m-1,7154,829 -35.5%   
CASH FLOW
From Operations Rs m881,231 7.1%  
From Investments Rs m-94-208 45.0%  
From Financial Activity Rs mNA-595 0.0%  
Net Cashflow Rs m-6427 -1.3%  

Share Holding

Indian Promoters % 0.0 55.4 -  
Foreign collaborators % 75.0 0.3 25,000.0%  
Indian inst/Mut Fund % 0.3 3.4 8.8%  
FIIs % 15.7 3.9 402.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 37.0 24.6%  
Shareholders   12,856 30,437 42.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NEULAND LABS  DR. REDDYS LAB  GSK PHARMA  ALEMBIC  PROCTER & GAMBLE HEALTH  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 531 Points; Reliance Industries & IndusInd Bank Fall 5%(Closing)

Indian share markets witnessed huge selling pressure today and failed to hold on to their opening gains as profit booking and weakness across all sectors erased gains.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

J.B.CHEMICALS Announces Quarterly Results (3QFY20); Net Profit Up 34.1% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, J.B.CHEMICALS has posted a net profit of Rs 622 m (up 34.1% YoY). Sales on the other hand came in at Rs 4 bn (up 9.3% YoY). Read on for a complete analysis of J.B.CHEMICALS's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 25, 2021 (Close)

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS